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DISCORDANT DIAGNOSES IN SARCOMA, GIST AND DESMOIDE TUMOUR IN
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A2, Ray Coquard I1, Ducimetière F1, Jean-Denis M1, Courrèges JB3, Mesli N2, Morelle M1,
Plommet N4, Blay JY1, Coindre JM3
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OBJECTIVES: Major discordant diagnoses may have strong impact on therapeutic
management. So, identification of major discordant diagnoses and predictive fac-
tors were conducted in sarcoma patients. METHODS: A multicenter analysis was
performed retrospectively from the prospective cohort of sarcoma patients. Inclu-
sion criteria were patients with a diagnosis of sarcoma in 2010 and with a second
opinion performed within the network RRePS (Réseau de Référence en Pathologie
des Sarcomes supported be the French NCI). Major discordant diagnoses were de-
fined as: sarcoma vs benign lesion, sarcoma vs malignant non sarcoma tumor,
gastrointestinal stromal tumors (GIST) vs non GIST, and desmoid tumor vs non
desmoid tumor. Patient and disease characteristics were described. Logistic regres-
sions were used in order to define predictive factors of major discordance.
RESULTS: 3621 patients were included in the study. 438 patients (12%) had a major
discordant diagnoses: sarcoma versus benign lesion (or conversely) in 155 patients
(58%); sarcoma instead of malignant non sarcoma tumor (or conversely) in 103
patients (24%); gastrointestinal stromal tumors (GIST) instead of non GIST in 48
patients (11%); desmoid tumor instead of non desmoid tumor in 28 patients (6%)
and other (4%). Major diagnostic discordances risks were higher (i) for malignant
non sarcoma tumors compared to GIST, liposarcoma, and other sarcoma histolog-
ical subtypes (p0.004); (ii) for patients who had a previous cancer (p0.03); (iii) for
limb localization compared to trunk (p0.004); (iv) when the second opinion was
requested by the initial pathologist (p0.01). CONCLUSIONS: This study reported
that sarcoma instead of benign lesion (or conversely) is the major discordant diag-
nosis in sarcoma patients implying that: (i) patients who should not be treated
received anticancer therapy; (ii) treatments are potentially delayed for patients
who should be rapidly treated. Economics evaluations are in progress in order to
advise health care administrators regarding systematic second reviews in the
management of sarcoma.
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APPLYING A VALUE-BASED PRICE ACROSS DIFFERENT DISEASE AREAS
Wilson T, Kusel J, Brooks-Rooney C, Costello S
Costello Medical Consulting Ltd., Cambridge, UK
OBJECTIVES: Value-based pricing is currently a topic of much interest, and there is
wide-spread speculation as to how it will be implemented. The aim of this research
was to address the question as to how reimbursement bodies will consider value-
based pricing with regard to pharmaceuticals that can be used in multiple indica-
tions. Will there be separate prices, or an average price weighted by the population
size of each different population? If so, then would the price have to be re-assessed
each time the drug is approved for a new indication? METHODS: The National
Institute for Health and Clinical Excellence (NICE) in the UK was used as an exam-
ple to identify those therapies that have been appraised for multiple indications.
All NICE technology assessments for cancer treatments published since January
2005 were reviewed. Therapies used in different indications were identified and
ICERs from these appraisals were extracted. RESULTS: In total, 12 different treat-
ments were identified, spanning sixteen different indications within cancer. Of
these, five (cetuximab, docetaxel, imatinib, pemetrexed and trastuzumab) had IC-
ERs that were either side of the £30,000 per QALY threshold across different disease
areas. For example, the ICERs associated with cetuximab were found to vary from
£6,400 (squamous cell cancer of the head and neck) to £90,000 (colorectal cancer)
per QALY. These data suggest that there may be a large discrepancy when consid-
ering value-based pricing across different cancer populations. CONCLUSIONS:
Across indications, the ICERs for a single therapy were found to vary dramatically.
Considering that almost half of therapies identified had ICERs either side of the
£30,000 per QALY threshold, these results highlight the potential problem associ-
ated with labelling a pharmacologic treatment with a single value-based price.
Therefore, a single price may not be appropriate, and alternative methods should
be considered by reimbursement bodies.
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OBJECTIVES: To assess the epidemiologic and economic burden of breast cancer
(BC) at any stage from a large population-based study. METHODS: Lombardy Re-
gion includes 9.9 million individuals. Eligible patients were identified through a
data warehouse (DENALI), which matches with a probabilistic linkage demo-
graphic, clinical and economic data of different Healthcare Administrative data-
bases. All female individuals who had a first hospital discharge with a IDC-9 CM
code 174.XX from 1st January 2004 were selected and followed up to 5 years. These
subjects were considered incident patients since they had no cause-specific hos-
pitalizations during 2000-2003 period. We calculated yearly incidence, mortality
and health care costs (hospitalizations, drugs and outpatient examinations/visits)
from the National Health Service’s perspective (NHS). RESULTS: A total of 50,868
eligible subjects (mean ageSD equals to 62.514.2) were identified. Incidence
patients were homogeneously distributed during the observational period: 20.5% in
2004, 20.1% in 2005, 19.7% in 2006, and 19.4% and 20.2 in 2007 and 2008. During the
2005-2008 period, the mean cost/patient-year for incident and prevalent cases
were: 12,973€ versus 4,428€ in 2005, 13,847€ versus 4,237€ in 2006, 14,742€ versus
4,400€ in 2007, 15,671€ versus 4,336€ in 2008. Of the total cost of incident patients,
hospitalizations were the driver (70%), with drugs and outpatient claims contrib-
uting to 16.3% and 16.2%, respectively. The driver of total costs in prevalent pa-
tients was drugs (41.1%), followed by hospitalizations and outpatients claims, con-
tributing to 37.1% and 21.8%, respectively. Overall 46.3 deaths/1,000 patients-year
were estimated with a probability of survival equals to 80% after 5 years from the
index date. CONCLUSIONS: The high epidemiological and economic burden of BC,
indicates the primary importance in monitoring the developing of the disease from
the NHS’s perspective. DENALI shows to be an efficient instrument combining
administrative databases to accurately estimate the burden of BC.
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OBJECTIVES: Health-related quality of life (HRQL) is an essential part of health
technology assessment; without this Quality Adjusted Life Years cannot be calcu-
lated. The objective of this study was to compare utilities calculated for patients
with advanced melanoma in the Phase III clinical trial for ipilimumab (MDX010-20)
with utilities produced by vignettes for advanced melanoma valued by the general
population. A comparison was also made between standard ‘progression-based’
utilities and those based on the time elapsed between the utility measurement and
the patient’s death. METHODS: Utilities from the trial were generated using the
EORTC-8D and SF-6D preference-based measures. Analyses by progression status
and time to death were conducted on patient-level data, and the prognostic value
of the methods was assessed. Patient-level results were then compared with the
utilities derived for progressive and non-progressive disease in a separate vignette
study. RESULTS: SF-6D and EORTC-8D showed a substantial decrease in utility in
the 180 days before the patient’s death (from 0.83 to 0.63 and from 0.66 to 0.51,
respectively), which is not consistent with the use of standard Markov progression-
based, health-state modelling. Time to death showed a lower Root Mean Squared
Error and higher R2when used to predict patient utility, demonstrating that they
produce a more accurate assessment of HRQL. Utilities taken from vignettes
showed a larger decrease on disease progression (from 0.77 to 0.59) than either the
generic SF-6D (from 0.64 to 0.62) or condition-specific EORTC-8D (from 0.80 to 0.76).
CONCLUSIONS: Although most oncology modelling is based around disease pro-
gression, this may not always be appropriate because the time to a patient’s death
appears to be a more accurate predictor of HRQL. This has implications for the
analysis of utility information in future cost-effectiveness studies as well as the
modelling methods used for oncology treatments and health technology assess-
ments.
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OBJECTIVES:The main aim of this paper is to develop a new approach for analyzing
EQ-5D data based on the principles of multicriteria analysis. A data set of 73 pa-
tients after lumbar discectomy has been used in order to illustrate the applicability
of the model.METHODS:The proposed approach is an ordinal regression model for
measuring and analyzing EQ-5D data. The main objective of the method is the
aggregation of individual judgments into a collective value function. The proposed
approach provides a series of normalized average indices for each one of the di-
mensions of the EQ-5D instrument, as well as a set of perceptual maps. These
results include: average satisfaction, demanding, and improvement indices, as
well as action and improvement diagrams. RESULTS: The analysis of the sample
revealed a relatively high satisfaction level (84.65%) for the general health status
(VAS). Furthermore, the analysis of the EQ-5D questions shows that patients are
very satisfied regarding the dimensions of self-care (95.67%) and pain/discomfort
(95.63%). On the other hand, the lowest health status score refers to the dimension
of mobility (78.24%). The weights of these five dimensions are additional results of
the proposed method. Based on this particular sample, the results show that the
most important factor is the anxiety/depression (32.11%), following by the dimen-
sions of mobility (21.23%) and usual activities (19.16%). Combing these results, the
action diagram reveals a gap regarding the perceptions of these particular patients
and proposes mobility and anxiety/depression as critical health status dimensions.
CONCLUSIONS: The main advantage of the method is the ability to consider the
qualitative (ordinal) nature of the input information. In addition, the provided
results are rich enough to give a clearer view about the patient’s health status.
CL2
STATISTICAL CONSIDERATIONS IN ESTIMATING SURVIVAL FOR ECONOMIC
EVALUATIONS IN ONCOLOGY
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